| Project/Area Number |
18K15523
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 52030:Psychiatry-related
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
Yoshinari Abe 京都府立医科大学, 医学(系)研究科(研究院), 助教 (50803631)
|
|---|
| Project Period (FY) |
2018-04-01 – 2023-03-31
|
| Project Status |
Completed (Fiscal Year 2022)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 強迫症 / Nアセチルシステイン / グルタミン酸 / MRI / 安静時機能的MRI / 被検者募集中 / 臨床研究審査委員会 / グルタミン酸系薬剤 |
|---|
| Outline of Final Research Achievements |
Concerning obsessive-compulsive disorder (OCD), the more detailed understandings of the pathophysiology and the more effective treatment methods are needed due to the poor outcomes of the present evidenced treatment strategies. N-acetylcysteine (NAC) is expected as a new therapeutic agent of OCD which modulates the glutamatergic neurons, while the details of its mechanisms are unclear. In the present study, 12-week treatment with NAC was provided for the patients with OCD, and we acquired MR images and serum concentrations of glutamate before and after the treatment to clarify the function of NAC. NAC improved OC symptoms and elevated the glutamate concentrations significantly, although it did not alter the structural MR images. The diffusion weighted images and the functional images are now under analysis.
|
| Academic Significance and Societal Importance of the Research Achievements |
NACの作用機序が明らかになることで、新たな作用機序のOCDの治療薬・治療法を開発できる可能性があり、またOCDに関連する他の精神疾患（強迫症関連症群に加えて摂食障害や依存症など）の治療法開発につながる可能性もある。
NACは副作用がほとんどなく、さらに他のグルタミン酸系薬剤として治療効果の期待されているメマンチンの常用量（20 mg）の薬価が439.70円であるのに対してNACの常用量（2400 mg）の薬価は50～100円程度で安価である。新たな選択肢として、NACによる効果メカニズムが明らかになれば強迫症の治療が大きく前進する。
|
